Ovarian Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Ovarian Cancer – Pipeline Review, H1 2017’, provides an overview of the Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer

The report reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ovarian Cancer therapeutics and enlists all their major and minor projects

The report assesses Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ovarian Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Adaptimmune Therapeutics Plc

Adgero Biopharmaceuticals Holdings Inc

Aduro BioTech Inc

Advanced Accelerator Applications SA

Advanced Cancer Therapeutics LLC

Advantagene Inc

Advenchen Laboratories LLC

Aeterna Zentaris Inc

Alethia Biotherapeutics Inc

Alkermes Plc

Almac Discovery Ltd

Alpha Cancer Technologies Inc

Alteogen Inc

Altor BioScience Corp

Ambrx Inc

Amgen Inc

Anavex Life Sciences Corp

ANP Technologies Inc

AntiCancer Inc

Antigen Express Inc

Antoxis Ltd

Aphios Corp

Aposense Ltd

Aprea AB

arGEN-X BV

ARMO Biosciences Inc

Armour Therapeutics Inc

Arno Therapeutics Inc

ArQule Inc

Array BioPharma Inc

Arrien Pharmaceuticals LLC

Arvinas Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Athenex Inc

AVEO Pharmaceuticals Inc

Avipep Pty Ltd

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene (Beijing) Co Ltd

Bio-Path Holdings Inc

BioCancell Ltd

BioMoti Ltd

Bionomics Ltd

BioNTech AG

Biotest AG

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

Cavion LLC

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellular Biomedicine Group Inc

Celon Pharma SA

Celprogen Inc

Celsion Corp

Celyad SA

Ceronco Biosciences

CerRx Inc

Chipscreen Biosciences Ltd

Cielo Therapeutics Inc

Clovis Oncology Inc

CohBar Inc

Coherus BioSciences Inc

Commence Bio Inc

Compliment Corp

Corcept Therapeutics Inc

Critical Outcome Technologies Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CytRx Corp

CZ BioMed Corp

DAE HWA Pharmaceutical Co Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Eli Lilly and Company

Endocyte Inc

EntreChem SL

Epigen Biosciences Inc

EpiThany Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Fate Therapeutics Inc

Forty Seven Inc

Fujifilm Corp

Galena Biopharma Inc

GamaMabs Pharma SA

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Genisphere LLC

Genmab A/S

Genor BioPharma Co Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GlycoNex Inc

Glycotope GmbH

GP Pharm SA

Gradalis Inc

GW Pharmaceuticals Plc

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Hemispherx Biopharma Inc

Horizon Pharma Plc

Ideaya Biosciences Inc

Ignyta Inc

Ildong Pharmaceutical Co Ltd

IMMD Inc

Immune Design Corp

Immune Pharmaceuticals Inc

Immune Therapeutics Inc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Immunovaccine Inc

IMPACT Therapeutics Inc

Incyte Corp

Innate Immunotherapeutics Ltd

Innate Pharma SA

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Insys Therapeutics Inc

Inventiva

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Komipharm International Co Ltd

Kyowa Hakko Kirin Co Ltd

La Jolla Pharmaceutical Company

Laboratoire HRA Pharma

Lantern Pharma Inc

LATITUDE Pharmaceuticals Inc

LegoChem Biosciences Inc

Lidds AB

Lion Biotechnologies Inc

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lymphocyte Activation Technologies SA

Mabion SA

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

MaxiVAX SA

Mebiopharm Co Ltd

Medestea Research & Production SpA

MediaPharma Srl

MedImmune LLC

Medivir AB

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Microlin Bio Inc

Millennium Pharmaceuticals Inc

Minerva Biotechnologies Corp

Moleculin Biotech Inc

MolMed SpA

Monopar Therapeutics LLC

Morphotek Inc

Mycenax Biotech Inc

NantKwest Inc

Natco Pharma Ltd

NBE-Therapeutics AG

Nektar Therapeutics

Neovacs SA

Nerviano Medical Sciences Srl

Neurimmune Holding AG

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

NovaTarg Therapeutics Inc

Noviga Research AB

Novogen Ltd

Noxopharm Ltd

NuCana BioMed Ltd

Oasmia Pharmaceutical AB

OBI Pharma Inc

Omeros Corp

Omnitura Therapeutics Inc

OncBioMune Pharmaceuticals Inc

Oncobiologics Inc

Oncodesign SA

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

OncoTartis Inc

OncoTherapy Science Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

ORCA Therapeutics BV

OSE Immunotherapeutics

Oxford BioMedica Plc

OXIS International Inc

Pangaea Biotech SL

Patrys Ltd

PDS Biotechnology Corp

PEP-Therapy SAS

Pfizer Inc

Pharma Mar SA

PharmAust Ltd

Pharmicell Co Ltd

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precision Biologics Inc

Prima BioMed Ltd

Probility Media Corp

Propanac Biopharma Inc

PsiOxus Therapeutics Ltd

Puma Biotechnology Inc

Quintessence Biosciences Inc

Radius Health Inc

Recepta Biopharma SA

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Rosetta Genomics Ltd

Rubicon Biotechnology Inc

RXi Pharmaceuticals Corp

Sanofi

Sanofi Pasteur SA

SATT North SAS

Selecta Biosciences Inc

Senhwa Biosciences Inc

Sequoia Sciences Inc

Siamab Therapeutics Inc

Sierra Oncology Inc

Sigma-Tau SpA

Sillajen Biotherapeutics

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sotio AS

Starpharma Holdings Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Supratek Pharma Inc

Susavion Biosciences Inc

Symic Biomedical Inc

Syndax Pharmaceuticals Inc

Syros Pharmaceuticals Inc

Tactiva Therapeutics LLC

Takeda Pharmaceutical Company Ltd

Takis Srl

TapImmune Inc

Targovax ASA

Tesaro Inc

The Female Health Company

TRACON Pharmaceuticals Inc

Transgene SA

TVAX Biomedical Inc

Tyrogenex Inc

ValiRx Plc

Vascular Biogenics Ltd

VentiRx Pharmaceuticals Inc

Verastem Inc

VG Life Sciences Inc

ViiV Healthcare Ltd

ViraTherapeutics GmbH

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 12

Ovarian Cancer - Overview 13

Ovarian Cancer - Therapeutics Development 14

Ovarian Cancer - Therapeutics Assessment 73

Ovarian Cancer - Companies Involved in Therapeutics Development 105

Ovarian Cancer - Drug Profiles 254

Ovarian Cancer - Dormant Projects 1928

Ovarian Cancer - Discontinued Products 1947

Ovarian Cancer - Product Development Milestones 1951

Appendix 1968

List of Tables

List of Tables

Number of Products under Development for Ovarian Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Companies, H1 2017 (Contd..25), H1 2017

Products under Development by Companies, H1 2017 (Contd..26), H1 2017

Products under Development by Companies, H1 2017 (Contd..27), H1 2017

Products under Development by Companies, H1 2017 (Contd..28), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ovarian Cancer – Pipeline by 3-V Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by 4SC AG, H1 2017

Ovarian Cancer – Pipeline by AB Science SA, H1 2017

Ovarian Cancer – Pipeline by AbbVie Inc, H1 2017

Ovarian Cancer – Pipeline by AbGenomics International Inc, H1 2017

Ovarian Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Ovarian Cancer – Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2017

Ovarian Cancer – Pipeline by Aduro BioTech Inc, H1 2017

Ovarian Cancer – Pipeline by Advanced Accelerator Applications SA, H1 2017

Ovarian Cancer – Pipeline by Advanced Cancer Therapeutics LLC, H1 2017

Ovarian Cancer – Pipeline by Advantagene Inc, H1 2017

Ovarian Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017

Ovarian Cancer – Pipeline by Aeterna Zentaris Inc, H1 2017

Ovarian Cancer – Pipeline by Alethia Biotherapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Alkermes Plc, H1 2017

Ovarian Cancer – Pipeline by Almac Discovery Ltd, H1 2017

Ovarian Cancer – Pipeline by Alpha Cancer Technologies Inc, H1 2017

Ovarian Cancer – Pipeline by Alteogen Inc, H1 2017

Ovarian Cancer – Pipeline by Altor BioScience Corp, H1 2017

Ovarian Cancer – Pipeline by Ambrx Inc, H1 2017

Ovarian Cancer – Pipeline by Amgen Inc, H1 2017

Ovarian Cancer – Pipeline by Anavex Life Sciences Corp, H1 2017

Ovarian Cancer – Pipeline by ANP Technologies Inc, H1 2017

Ovarian Cancer – Pipeline by AntiCancer Inc, H1 2017

Ovarian Cancer – Pipeline by Antigen Express Inc, H1 2017

Ovarian Cancer – Pipeline by Antoxis Ltd, H1 2017

Ovarian Cancer – Pipeline by Aphios Corp, H1 2017

Ovarian Cancer – Pipeline by Aposense Ltd, H1 2017

Ovarian Cancer – Pipeline by Aprea AB, H1 2017

Ovarian Cancer – Pipeline by arGEN-X BV, H1 2017

Ovarian Cancer – Pipeline by ARMO Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Armour Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Arno Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by ArQule Inc, H1 2017

Ovarian Cancer – Pipeline by Array BioPharma Inc, H1 2017

Ovarian Cancer – Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Ovarian Cancer – Pipeline by Arvinas Inc, H1 2017

Ovarian Cancer – Pipeline by Astellas Pharma Inc, H1 2017

Ovarian Cancer – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by AstraZeneca Plc, H1 2017

Ovarian Cancer – Pipeline by Atara Biotherapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Athenex Inc, H1 2017

Ovarian Cancer – Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Avipep Pty Ltd, H1 2017

Ovarian Cancer – Pipeline by Basilea Pharmaceutica Ltd, H1 2017

Ovarian Cancer – Pipeline by Bavarian Nordic A/S, H1 2017

Ovarian Cancer – Pipeline by Bayer AG, H1 2017

Ovarian Cancer – Pipeline by BeiGene (Beijing) Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Bio-Path Holdings Inc, H1 2017

Ovarian Cancer – Pipeline by BioCancell Ltd, H1 2017

Ovarian Cancer – Pipeline by BioMoti Ltd, H1 2017

Ovarian Cancer – Pipeline by Bionomics Ltd, H1 2017

Ovarian Cancer – Pipeline by BioNTech AG, H1 2017

Ovarian Cancer – Pipeline by Biotest AG, H1 2017

Ovarian Cancer – Pipeline by Biscayne Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Ovarian Cancer – Pipeline by Boston Biomedical Inc, H1 2017

Ovarian Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2017

Ovarian Cancer – Pipeline by Calithera Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by CASI Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Cavion LLC, H1 2017

Ovarian Cancer – Pipeline by CBT Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Celgene Corp, H1 2017

Ovarian Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Cellectar Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Celleron Therapeutics Ltd, H1 2017

Ovarian Cancer – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Ovarian Cancer – Pipeline by Celon Pharma SA, H1 2017

Ovarian Cancer – Pipeline by Celprogen Inc, H1 2017

Ovarian Cancer – Pipeline by Celsion Corp, H1 2017

Ovarian Cancer – Pipeline by Celyad SA, H1 2017

Ovarian Cancer – Pipeline by Ceronco Biosciences, H1 2017

Ovarian Cancer – Pipeline by CerRx Inc, H1 2017

Ovarian Cancer – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Ovarian Cancer – Pipeline by Cielo Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Clovis Oncology Inc, H1 2017

Ovarian Cancer – Pipeline by CohBar Inc, H1 2017

Ovarian Cancer – Pipeline by Coherus BioSciences Inc, H1 2017

Ovarian Cancer – Pipeline by Commence Bio Inc, H1 2017

Ovarian Cancer – Pipeline by Compliment Corp, H1 2017

Ovarian Cancer – Pipeline by Corcept Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Critical Outcome Technologies Inc, H1 2017

Ovarian Cancer – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by CytomX Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Cytori Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by CytRx Corp, H1 2017

Ovarian Cancer – Pipeline by CZ BioMed Corp, H1 2017

Ovarian Cancer – Pipeline by DAE HWA Pharmaceutical Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Ovarian Cancer – Pipeline by DEKK-TEC Inc, H1 2017

Ovarian Cancer – Pipeline by DelMar Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Ovarian Cancer – Pipeline by Ecrins Therapeutics SAS, H1 2017

Ovarian Cancer – Pipeline by Eisai Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Eli Lilly and Company, H1 2017

Ovarian Cancer – Pipeline by Endocyte Inc, H1 2017

Ovarian Cancer – Pipeline by EntreChem SL, H1 2017

Ovarian Cancer – Pipeline by Epigen Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by EpiThany Inc, H1 2017

Ovarian Cancer – Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Exelixis Inc, H1 2017

Ovarian Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Ovarian Cancer – Pipeline by Faron Pharmaceuticals Oy, H1 2017

Ovarian Cancer – Pipeline by Fate Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Forty Seven Inc, H1 2017

Ovarian Cancer – Pipeline by Fujifilm Corp, H1 2017

Ovarian Cancer – Pipeline by Galena Biopharma Inc, H1 2017

Ovarian Cancer – Pipeline by GamaMabs Pharma SA, H1 2017

Ovarian Cancer – Pipeline by Gene Techno Science Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Genelux Corp, H1 2017

Ovarian Cancer – Pipeline by Genentech Inc, H1 2017

Ovarian Cancer – Pipeline by Genisphere LLC, H1 2017

Ovarian Cancer – Pipeline by Genmab A/S, H1 2017

Ovarian Cancer – Pipeline by Genor BioPharma Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Gilead Sciences Inc, H1 2017

Ovarian Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017

Ovarian Cancer – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Ovarian Cancer – Pipeline by GlycoNex Inc, H1 2017

Ovarian Cancer – Pipeline by Glycotope GmbH, H1 2017

Ovarian Cancer – Pipeline by GP Pharm SA, H1 2017

Ovarian Cancer – Pipeline by Gradalis Inc, H1 2017

Ovarian Cancer – Pipeline by GW Pharmaceuticals Plc, H1 2017

Ovarian Cancer – Pipeline by Halozyme Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Hemispherx Biopharma Inc, H1 2017

Ovarian Cancer – Pipeline by Horizon Pharma Plc, H1 2017

Ovarian Cancer – Pipeline by Ideaya Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Ignyta Inc, H1 2017

Ovarian Cancer – Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017

Ovarian Cancer – Pipeline by IMMD Inc, H1 2017

Ovarian Cancer – Pipeline by Immune Design Corp, H1 2017

Ovarian Cancer – Pipeline by Immune Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Immune Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Immunocore Ltd, H1 2017

Ovarian Cancer – Pipeline by ImmunoGen Inc, H1 2017

Ovarian Cancer – Pipeline by Immunomedics Inc, H1 2017

Ovarian Cancer – Pipeline by Immunovaccine Inc, H1 2017

Ovarian Cancer – Pipeline by IMPACT Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Incyte Corp, H1 2017

Ovarian Cancer – Pipeline by Innate Immunotherapeutics Ltd, H1 2017

Ovarian Cancer – Pipeline by Innate Pharma SA, H1 2017

Ovarian Cancer – Pipeline by Innovation Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Insys Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Inventiva, H1 2017

Ovarian Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Johnson & Johnson, H1 2017

Ovarian Cancer – Pipeline by Juno Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Komipharm International Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Ovarian Cancer – Pipeline by La Jolla Pharmaceutical Company, H1 2017

Ovarian Cancer – Pipeline by Laboratoire HRA Pharma, H1 2017

Ovarian Cancer – Pipeline by Lantern Pharma Inc, H1 2017

Ovarian Cancer – Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by LegoChem Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Lidds AB, H1 2017

Ovarian Cancer – Pipeline by Lion Biotechnologies Inc, H1 2017

Ovarian Cancer – Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Ovarian Cancer – Pipeline by Loxo Oncology Inc, H1 2017

Ovarian Cancer – Pipeline by Lymphocyte Activation Technologies SA, H1 2017

Ovarian Cancer – Pipeline by Mabion SA, H1 2017

Ovarian Cancer – Pipeline by MabVax Therapeutics Holdings Inc, H1 2017

Ovarian Cancer – Pipeline by MacroGenics Inc, H1 2017

Ovarian Cancer – Pipeline by Mateon Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by MaxiVAX SA, H1 2017

Ovarian Cancer – Pipeline by Mebiopharm Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Medestea Research & Production SpA, H1 2017

Ovarian Cancer – Pipeline by MediaPharma Srl, H1 2017

Ovarian Cancer – Pipeline by MedImmune LLC, H1 2017

Ovarian Cancer – Pipeline by Medivir AB, H1 2017

Ovarian Cancer – Pipeline by Merck & Co Inc, H1 2017

Ovarian Cancer – Pipeline by Merck KGaA, H1 2017

Ovarian Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Mersana Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Merus NV, H1 2017

Ovarian Cancer – Pipeline by Microlin Bio Inc, H1 2017

Ovarian Cancer – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Minerva Biotechnologies Corp, H1 2017

Ovarian Cancer – Pipeline by Moleculin Biotech Inc, H1 2017

Ovarian Cancer – Pipeline by MolMed SpA, H1 2017

Ovarian Cancer – Pipeline by Monopar Therapeutics LLC, H1 2017

Ovarian Cancer – Pipeline by Morphotek Inc, H1 2017

Ovarian Cancer – Pipeline by Mycenax Biotech Inc, H1 2017

Ovarian Cancer – Pipeline by NantKwest Inc, H1 2017

Ovarian Cancer – Pipeline by Natco Pharma Ltd, H1 2017

Ovarian Cancer – Pipeline by NBE-Therapeutics AG, H1 2017

Ovarian Cancer – Pipeline by Nektar Therapeutics, H1 2017

Ovarian Cancer – Pipeline by Neovacs SA, H1 2017

Ovarian Cancer – Pipeline by Nerviano Medical Sciences Srl, H1 2017

Ovarian Cancer – Pipeline by Neurimmune Holding AG, H1 2017

Ovarian Cancer – Pipeline by NewLink Genetics Corp, H1 2017

Ovarian Cancer – Pipeline by Northwest Biotherapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Novartis AG, H1 2017

Ovarian Cancer – Pipeline by NovaTarg Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Noviga Research AB, H1 2017

Ovarian Cancer – Pipeline by Novogen Ltd, H1 2017

Ovarian Cancer – Pipeline by Noxopharm Ltd, H1 2017

Ovarian Cancer – Pipeline by NuCana BioMed Ltd, H1 2017

Ovarian Cancer – Pipeline by Oasmia Pharmaceutical AB, H1 2017

Ovarian Cancer – Pipeline by OBI Pharma Inc, H1 2017

Ovarian Cancer – Pipeline by Omeros Corp, H1 2017

Ovarian Cancer – Pipeline by Omnitura Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Oncobiologics Inc, H1 2017

Ovarian Cancer – Pipeline by Oncodesign SA, H1 2017

Ovarian Cancer – Pipeline by Oncolix Inc, H1 2017

Ovarian Cancer – Pipeline by Oncolytics Biotech Inc, H1 2017

Ovarian Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by OncoTartis Inc, H1 2017

Ovarian Cancer – Pipeline by OncoTherapy Science Inc, H1 2017

Ovarian Cancer – Pipeline by Oncternal Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Opsona Therapeutics Ltd, H1 2017

Ovarian Cancer – Pipeline by Optimum Therapeutics LLC, H1 2017

Ovarian Cancer – Pipeline by ORCA Therapeutics BV, H1 2017

Ovarian Cancer – Pipeline by OSE Immunotherapeutics, H1 2017

Ovarian Cancer – Pipeline by Oxford BioMedica Plc, H1 2017

Ovarian Cancer – Pipeline by OXIS International Inc, H1 2017

Ovarian Cancer – Pipeline by Pangaea Biotech SL, H1 2017

Ovarian Cancer – Pipeline by Patrys Ltd, H1 2017

Ovarian Cancer – Pipeline by PDS Biotechnology Corp, H1 2017

Ovarian Cancer – Pipeline by PEP-Therapy SAS, H1 2017

Ovarian Cancer – Pipeline by Pfizer Inc, H1 2017

Ovarian Cancer – Pipeline by Pharma Mar SA, H1 2017

Ovarian Cancer – Pipeline by PharmAust Ltd, H1 2017

Ovarian Cancer – Pipeline by Pharmicell Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Plexxikon Inc, H1 2017

Ovarian Cancer – Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Precision Biologics Inc, H1 2017

Ovarian Cancer – Pipeline by Prima BioMed Ltd, H1 2017

Ovarian Cancer – Pipeline by Probility Media Corp, H1 2017

Ovarian Cancer – Pipeline by Propanac Biopharma Inc, H1 2017

Ovarian Cancer – Pipeline by PsiOxus Therapeutics Ltd, H1 2017

Ovarian Cancer – Pipeline by Puma Biotechnology Inc, H1 2017

Ovarian Cancer – Pipeline by Quintessence Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Radius Health Inc, H1 2017

Ovarian Cancer – Pipeline by Recepta Biopharma SA, H1 2017

Ovarian Cancer – Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Rgenix Inc, H1 2017

Ovarian Cancer – Pipeline by Richter Gedeon Nyrt, H1 2017

Ovarian Cancer – Pipeline by Rosetta Genomics Ltd, H1 2017

Ovarian Cancer – Pipeline by Rubicon Biotechnology Inc, H1 2017

Ovarian Cancer – Pipeline by RXi Pharmaceuticals Corp, H1 2017

Ovarian Cancer – Pipeline by Sanofi, H1 2017

Ovarian Cancer – Pipeline by Sanofi Pasteur SA, H1 2017

Ovarian Cancer – Pipeline by SATT North SAS, H1 2017

Ovarian Cancer – Pipeline by Selecta Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Senhwa Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Sequoia Sciences Inc, H1 2017

Ovarian Cancer – Pipeline by Siamab Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Sierra Oncology Inc, H1 2017

Ovarian Cancer – Pipeline by Sigma-Tau SpA, H1 2017

Ovarian Cancer – Pipeline by Sillajen Biotherapeutics, H1 2017

Ovarian Cancer – Pipeline by Soricimed Biopharma Inc, H1 2017

Ovarian Cancer – Pipeline by Sorrento Therapeutics Inc, H1 2017

Ovarian Cancer – Pipeline by Sotio AS, H1 2017

Ovarian Cancer – Pipeline by Starpharma Holdings Ltd, H1 2017

Ovarian Cancer – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Ovarian Cancer – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Ovarian Cancer – Pipeline by Supratek Pharma Inc, H1 2017

Ovarian Cancer – Pipeline by Susavion Biosciences Inc, H1 2017

Ovarian Cancer – Pipeline by Symic Biomedical Inc, H1 2017

Ovarian Cancer – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Syros Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Tactiva Therapeutics LLC, H1 2017

Ovarian Cancer – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Ovarian Cancer – Pipeline by Takis Srl, H1 2017

Ovarian Cancer – Pipeline by TapImmune Inc, H1 2017

Ovarian Cancer – Pipeline by Targovax ASA, H1 2017

Ovarian Cancer – Pipeline by Tesaro Inc, H1 2017

Ovarian Cancer – Pipeline by The Female Health Company, H1 2017

Ovarian Cancer – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Transgene SA, H1 2017

Ovarian Cancer – Pipeline by TVAX Biomedical Inc, H1 2017

Ovarian Cancer – Pipeline by Tyrogenex Inc, H1 2017

Ovarian Cancer – Pipeline by ValiRx Plc, H1 2017

Ovarian Cancer – Pipeline by Vascular Biogenics Ltd, H1 2017

Ovarian Cancer – Pipeline by VentiRx Pharmaceuticals Inc, H1 2017

Ovarian Cancer – Pipeline by Verastem Inc, H1 2017

Ovarian Cancer – Pipeline by VG Life Sciences Inc, H1 2017

Ovarian Cancer – Pipeline by ViiV Healthcare Ltd, H1 2017

Ovarian Cancer – Pipeline by ViraTherapeutics GmbH, H1 2017

Ovarian Cancer – Pipeline by Zymeworks Inc, H1 2017

Ovarian Cancer – Dormant Projects, H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..2), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..3), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..4), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..5), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..6), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..7), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..8), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..9), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..10), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..11), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..12), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..13), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..14), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..15), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..16), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..17), H1 2017

Ovarian Cancer – Dormant Projects, H1 2017 (Contd..18), H1 2017

Ovarian Cancer – Discontinued Products, H1 2017

Ovarian Cancer – Discontinued Products, H1 2017 (Contd..1), H1 2017

Ovarian Cancer – Discontinued Products, H1 2017 (Contd..2), H1 2017

Ovarian Cancer – Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

List of Figures

Number of Products under Development for Ovarian Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports